Paper39367387
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
Vandewalle N and 8 others. Exp Hematol Oncol, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies. Papers, record 39367387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39367387
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| G0A8522N, 1S66121N | Fonds voor Wetenschappelijk Onderzoek Vlaanderen | PubMed | ||
| G0A8522N, 1S66121N | Fonds voor Wetenschappelijk Onderzoek Vlaanderen | PubMed | ||
| SRP-84 | Vrije Universiteit Brussel | PubMed | ||
| KotK_VUB/ 2021/12786/1 | Kom Op Tegen Kanker | PubMed |
Source PubMed
References152
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26794130 | Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis. | Dis Model Mech | 2016 | https://conductscience.org/library/papers/26794130 | PubMed |
| 2 | 24904064 | Axl receptor tyrosine kinase expression in breast cancer. | J Clin Pathol | 2014 | https://conductscience.org/library/papers/24904064 | PubMed |
| 3 | 17325667 | A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. | Oncogene | 2007 | https://conductscience.org/library/papers/17325667 | PubMed |
| 4 | 9671397 | Determinants for transformation induced by the Axl receptor tyrosine kinase. | Oncogene | 1998 | https://conductscience.org/library/papers/9671397 | PubMed |
| 5 | 30189359 | AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking. | Neoplasia | 2018 | https://conductscience.org/library/papers/30189359 | PubMed |
| 6 | 34244439 | The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34244439 | PubMed |
| 7 | 32660000 | Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32660000 | PubMed |
| 8 | 33268594 | TP-0903 is active in models of drug-resistant acute myeloid leukemia. | JCI Insight | 2020 | https://conductscience.org/library/papers/33268594 | PubMed |
| 9 | 28645776 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28645776 | PubMed |
| 10 | 34266948 | Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34266948 | PubMed |
| 11 | 23648337 | AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. | Mol Cell Endocrinol | 2013 | https://conductscience.org/library/papers/23648337 | PubMed |
| 12 | 29386018 | Targeting Gas6/TAM in cancer cells and tumor microenvironment. | Mol Cancer | 2018 | https://conductscience.org/library/papers/29386018 | PubMed |
| 13 | 33127875 | New directions for emerging therapies in acute myeloid leukemia: the next chapter. | Blood Cancer J | 2020 | https://conductscience.org/library/papers/33127875 | PubMed |
| 14 | 24022140 | First Axl inhibitor enters clinical trials. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/24022140 | PubMed |
| 15 | 35311091 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. | Front Oncol | 2022 | https://conductscience.org/library/papers/35311091 | PubMed |
| 16 | 26763248 | Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26763248 | PubMed |
| 17 | 27549806 | Axl signaling induces development of natural killer cells in vitro and in vivo. | Protoplasma | 2017 | https://conductscience.org/library/papers/27549806 | PubMed |
| 18 | 17655729 | FLT3 inhibition in acute myeloid leukaemia. | Br J Haematol | 2007 | https://conductscience.org/library/papers/17655729 | PubMed |
| 19 | 25344858 | Axl as a mediator of cellular growth and survival. | Oncotarget | 2014 | https://conductscience.org/library/papers/25344858 | PubMed |
| 20 | 34400415 | Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34400415 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42466468 | FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches. | RSC Adv | 2026 | https://conductscience.org/library/papers/42466468 | PubMed |
| 42101422 | TAM receptor tyrosine kinases as potential mediators of the non-lytic spread of non-enveloped viruses. | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42101422 | PubMed |
| 41916916 | [Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance]. | Zhongguo Fei Ai Za Zhi | 2026 | https://conductscience.org/library/papers/41916916 | PubMed |
| 41446729 | IFNγ signaling drives resistance to FLT3 inhibition in acute myeloid leukemia. | iScience | 2025 | https://conductscience.org/library/papers/41446729 | PubMed |
| 41095933 | Targeted Therapies Modulating Mesenchymal-Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib. | J Clin Med | 2025 | https://conductscience.org/library/papers/41095933 | PubMed |
| 41011010 | The Receptor Tyrosine Kinase Axl in (Advanced) Gastric Cancer-From Pathophysiology to Therapeutic Impact. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41011010 | PubMed |
| 40464185 | Recent Advances in FLT3-Based Dual Inhibitors: A Promising Strategy for the Treatment of Acute Myeloid Leukemia. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/40464185 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AXL | 558 | PubTator's text mining | https://conductscience.org/library/genes/558 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39367387
GET https://conductscience.org/api/papers/v1/39367387/references?page=2